Global Ophthalmic Mitomycin C Market By Route of Administration (Topical Route, IV Route), By Indication (Glaucoma Surgery, Refractive Surgery, Pterygium Surgery, Ocular Surface Tumors and Others) and By Region – Global Forecast to 2031

MarketResearch.biz announces publication of its most recently generated research report titled, “Global Ophthalmic Mitomycin C Market by Route of Administration (Topical Route, IV Route), By Indication (Glaucoma Surgery, Refractive Surgery, Pterygium Surgery, Ocular Surface Tumors, Other Indications), and by Region – Global Forecast to 2031”, which offers a holistic view of the global ophthalmic mitomycin c market through systematic segmentation that covers every aspect of the target market. The Global Ophthalmic Mitomycin C Market is projected to be US$ 43.0 Mn in 2021 to reach US$ 36.9 Mn by 2031 at a CAGR of -1.5%.

Request Covid - 19 Impact

Mitomycin C is used as a chemotherapeutic agent due to its antitumor properties. In most of the cases, it is administered intravenously. It is an anti-metabolite with an anti-proliferative effect on cells showing the highest rate of mitosis by inhibiting DNA synthesis and interferes with RNA transcription and protein synthesis. Without the correct RNA and DNA, cell migration and mitosis are inhibited. This results in a decreased rate of cell proliferation. It is also used in eye surgery to prevent scarring during glaucoma filtering surgery, and also to prevent haze development after LASIK (Laser-Assisted Sub-Epithelial Keratectomy). Mitomycin C works by interfering with the development of genetic materials in cells, i.e. DNA. Mitomycin C prevents it from dividing into 2 cells, ultimately killing the cell.

Several awareness programs concerned with eye cancer have been initiated in various developed and developing countries. For instance, World Retinoblastoma Awareness Week is organized and managed by various NGOs across the globe, as retinoblastoma is a rare cancer that mostly occurs in children. Such awareness programs encourage individuals to pursue appropriate treatment and timely testing of such diseases. This factor is also expected to boost market growth prospects for the Mitomycin C sector.

The prevalence of glaucoma is increasing worldwide, with approximately 76 million people suffering from glaucoma in 2020. Trabeculectomy is performed as a treatment for glaucoma, and Mitomycin C is used during the initial stages to prevent excessive postoperative scarring, and thus ultimately reducing the risk of potential failure. Moreover, awareness programs concerning glaucoma initiated by various governments also emphasize early detection and treatment of these diseases. For example, the World Glaucoma Week is a global initiative by the World Glaucoma Association (WGA) to raise awareness on glaucoma. These factors are expected to create lucrative opportunities for major players as greater awareness levels are expected to lead to higher treatment adoption rates by patients.

Global Ophthalmic Mitomycin C Market Revenue (US$ Mn), 2021–2031

The side effects of Mitomycin C include ocular pain, photophobia, lacrimation, lid edema, dizziness, and temporary hair loss, among others. This factor is expected to potentially hamper the market revenue growth of the Mitomycin C sector to a certain extent. Moreover, the onset of the COVID-19 pandemic has resulted in either a complete shutdown of various businesses, or their functioning with minimal staff, as well as disruptions faced by numerous sourcing, manufacture & supply-chain operators, resulting in irreversible damage to each region's respective economic landscape. This is expected to have a profoundly negative impact on the Mitomycin C market as well. Respective lockdowns have restricted the manufacturing, as well as import/export of medicines. However, as enforced lockdowns are gradually lifted, and economies begin to reopen, the manufacturing of various drugs and biologics are also expected to commence, subsequently leading to a moderate recovery in the years to come.

Global Ophthalmic Mitomycin C Market Attractiveness Analysis by Route Of Administration, 2014–2031

The research report on the global ophthalmic mitomycin c market includes profiles of some of the major companies such as Mobius Therapeutics, LLC, Edge Pharma, LLC, etc.

Global Ophthalmic Mitomycin C Market Segmentation Based on Route of Administration, Indications, and Region

Based on Route of Administration:

• Topical Route
• IV Route

Based on Indications:

• Glaucoma Surgery
• Refractive Surgery
• Pterygium Surgery
• Ocular Surface Tumors
• Other Indications

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa